We investigated the development of binding and neutralizing antibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients receiving prolonged therapy with GM-CSF as adjuvant therapy of melanoma and the impact of these antibodies on biological effects.
P
atients with a thick primary melanoma (Z4 mm) or melanoma metastatic to regional lymph nodes are at high risk for melanoma recurrence and death. 1, 2 Currently, in 2014, high-dose interferon alfa-2b (IFN-a) and peginterferon alfa-2b (pegIFN-a2b) are the only agents approved by the Federal Food and Drug Administration (FDA) for adjuvant therapy of this patient population. These treatments have marginal efficacy. Whereas IFN does prolong progression-free survival, the overall survival benefit is minimal. [3] [4] [5] Moreover, the regimens are associated with considerable toxicity. These considerations led the National Comprehensive Cancer Network (NCCN) in 2014 to recommend participation in a clinical trial or observation for these patients. 6 The NCCN Panel relegated treatment with IFN-a to category 2B, meaning that there is a lower level of evidence and no uniform NCCN consensus. It is clear that more effective, less toxic treatments are needed for adjuvant therapy of melanoma patients who are at high risk for recurrence. Prospective phase III randomized pivotal trials of other agents for adjuvant therapy of melanoma are ongoing, 7 including a trial of ipilimumab versus observation, ipilimumab versus IFN-a, and trials of 2 vaccines (MAGE-A3 and a polyvalent melanoma vaccine, Pol-103A), but final results have not yet been released. An interim analysis of the MAGE-A3 trial showed that the study did not meet its first coprimary endpoint as it did not significantly extend disease-free survival in the overall patient population. Analysis regarding the second coprimary endpoint of efficacy in patients who demonstrate a favorable gene signature will be reported in 2015. An interim analysis of the trial of ipilimumab versus observation showed that it met its primary endpoint of improved progression-free survival. 8 A prospective randomized multicenter phase III trial intended to test the efficacy of GM-CSF (Leukine) versus vaccine versus placebo as adjuvant therapy of melanoma (E4697) is ongoing. Accrual to this trial has now been completed and preliminary results reported, 9 but patients are still being followed, and the study is expected to be completed in 2014.
GM-CSF is a hematopoietic growth factor, which stimulates proliferation and differentiation of hematopoietic progenitor cells and is approved for this purpose. 10 In addition, GM-CSF has immunologic activities that play a vital role in various diverse functions of the immune system. These include its ability to activate macrophages, which distinguish tumor cells from normal cells and kill only the tumor cells, 9 stimulation of peripheral blood monocytes in vitro to become cytotoxic for human melanoma cells, 10,11 production of monocyte activation and tumoricidal activity following in vivo administration, 11, 12 and stimulation of production of an angiogenesis inhibitor by macrophages. 13 GM-CSF also serves as the principal mediator of proliferation, maturation, and migration of dendritic cells, [14] [15] [16] antigen-presenting cells that play a major role in the induction of primary and secondary T-cell immune responses.
These considerations led to the design and conduct of several small hypothesis-generating clinical trials, which showed that administration of GM-CSF might offer clinical benefit as adjuvant therapy of melanoma. [17] [18] [19] [20] Moreover, a randomized phase II trial of GM-CSF + ipilimumab versus ipilimumab monotherapy for patients with metastatic melanoma suggested that patients treated with the combination enjoyed significantly longer overall survival and less toxicity than patients treated with ipilimumab monotherapy. 21 GM-CSF is a recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. Like the native protein, it is a glycoprotein of 127 amino acids but differs from the native protein in molecular mass. 22, 23 Moreover, the amino acid sequence of GM-CSF differs from the natural human GM-CSF by a substitution of leucine at position 23, and glycosylation is different from that of the native protein. These differences from the native GM-CSF could lead to immunogenicity of this molecule. In this study, we evaluated the biological effects of GM-CSF on the white blood cell (WBC) and percent eosinophils because these are routine clinical laboratory tests available to all physicians who are treating patients with GM-CSF. In addition, we performed serial determinations of serum neopterin levels as a means to measure monocyte/macrophage activation, as release of neopterin is a sign of macrophage activation 24, 25 and administration of GM-CSF results in increased production of neopterin. 26, 27 The approved use of GM-CSF is for short-term administration. Long-term (1 y) administration of GM-CSF does not appear to be associated with untoward clinical side effects. In this report, we present results of a systematic evaluation of the development of antibodies to GM-CSF in patients treated with prolonged GM-CSF therapy and the effect of such antibody development on the biological effects of GM-CSF.
PATIENTS AND METHODS

Patients
Fifty-three adult patients with histologically proven melanoma who were at high risk for recurrence (AJCC stage II [T4], III, and IV surgically excised) were enrolled in a clinical trial to determine the effect of adjuvant treatment with GM-CSF on immune and biological responses. Eligible patients were those in whom all known melanoma had been excised and had no evidence of disease on metastatic workup. Patients were required to start treatment with the study drug within 90 days of the last surgical procedure in which melanoma was present. Prior treatment with other adjuvant therapies, including IFN, before disease recurrence that led to study eligibility was allowed and adjuvant radiation therapy was allowed. The research protocol was approved by the relevant Institutional Review Boards and all participants gave written informed consent. The trial was registered on ClinicalTrials.gov with Identifier NCT00350597.
Patients were treated with GM-GSF, 125 mg/m 2 once daily (maximum dose 250 mg) subcutaneously for 14 days, followed by 14 days rest (28-d cycle). Treatment was continued for 1 year (thirteen 28-d cycles) or until disease progression that required systemic therapy. Blood samples for testing of the biological effects of GM-CSF (WBC, differential cell count, and serum neopterin levels) were keyed to the timing of GM-CSF administration (Fig. 1) . The samples were obtained on study day 0 (pretreatment), day 15 (after 14 d of GM-CSF treatment in the first cycle), day 29 (after 14 d of rest in the first cycle), day 155 (after 14 d of treatment in the sixth cycle), and day 351 (after 14 d of treatment in the 13th cycle). Serum samples for determination of binding and neutralizing antibodies to GM-CSF were obtained at the same time points. The serum was separated, stored frozen at À701C, and shipped in batches from the clinical site to the test site.
Assays for Anti-GM-CSF Antibodies
Assays to evaluate both binding antibodies and neutralizing antibodies were developed for use in human serum. Cutoff point, selectivity, sensitivity, precision, freeze and thaw stability, short-term stability, long-term stability, linearity of dilutions, parallelism, recovery, and robustness/ruggedness of the method have been studied. However, these assays would not allow us to distinguish whether the anti-GM-CSF antibodies are neutralizing or that the apparent neutralizing effect was due to high-titer binding antibodies.
Binding Antibodies
The measurement of binding antibodies is based on a qualitative bridging assay design, in which antibody in the sample is bound bivalently (eg, IgG) or multivalently (eg, IgM) to biotinylated GM-CSF captured to streptavidin-coated wells in a 96-well microtiter plate and detected using Europium radioisotope (Eu)-labeled GM-CSF.
Briefly, biotinylated GM-CSF (10 ng/well) is applied to streptavidin-coated wells. After incubation with slow shaking at room temperature, the wells are washed. Subsequently, calibration standards, quality control (QC) samples, or study samples are applied to the wells, followed by the addition of assay buffer. After incubation and slow shaking at room temperature, the wells are washed. Subsequently, Eu-labeled GM-CSF (50 ng/well) is added and incubated. After washing, the Enhancement Solution is added to each well and incubated. Finally, the plates are submitted for Eu-measurement using the Victor multilabel reader (Perkin-Elmer Life Sciences, Turku, Finland).
Neutralizing Antibodies
The bioassay is based on the TF-1 cell line, the growth of which is highly dependent on GM-CSF concentration. The TF-1 cell-based bioassay is calibrated with GM-CSF. QC and study samples are added to TF-1 cells and grown with a constant amount of GM-CSF (1.00 IU/mL). In the presence of neutralizing antibodies the proliferation of TF-1 cells is decreased. Proliferation is measured using commercially available DELFIA cell proliferation kit (Perkin-Elmer Life Sciences) on the basis of the measurement of 5-bromo-2 0 -deoxyuridine (BrdU) incorporation during DNA synthesis in proliferating cells.
Briefly, GM-CSF calibration standards + assay media and QC or study samples + assay media + GM-CSF (1.00 IU/mL) are added to the wells of 96-well microtiter plates and incubated for 1 to 2 h at 371C. Subsequently, a TF-1 cell suspension (2000 cells/ well) is added. Plates are then incubated at 371C in an atmosphere of 5% CO 2 . Then the anti-BrdU-Eu solution is added (40 mL/ well). Plates are again incubated at 371C (5% CO 2 ) followed by washing and incubation steps, and the measurement of timeresolved fluorescence according to manufacturer's instructions.
Sample Analysis Scheme
A 4-step sample analysis scheme has been used: (I) Initial immunoassay screening assay: All study samples were assessed to be either positive or negative for binding antibodies, on the basis of an assay plate-specific cutoff point. The cutoff point has been determined by calculating the average of matrix blank values multiplied by a constant cutoff point factor of 5.16 (determined using 95th percentile, corresponding to 5% false-positive rate, during the assay evaluation phase using sera from healthy individuals, n = 27). This procedure using an assay plate-specific cutoff point has been applied to control interassay variability (day-to-day variability and change of materials or reagents). (II) Confirmatory assay: Samples determined as potentially positive for binding antibodies in the initial screening assay (signal above cutoff point) were further investigated by means of an immunodepletion experiment. An excess amount of GM-CSF was added to the wells containing study samples. A sample was considered as true positive for binding antibodies if the signal was reduced below 50% compared with the reference signal (no GM-CSF added). (III) Cell-based neutralizing antibody assay: Study samples previously confirmed positive for total binding antibodies were further tested for neutralizing antibodies against GM-CSF. Sample values below the specific cutoff point of 0.158 IU/mL (determined using mean À 3 ÂSD, corresponding to 0.1% false-positive rate, of the LN converted concentrations from sera of healthy individuals, n = 21) are determined positive and values at or above the cutoff point are determined negative for neutralizing antibodies. (IV) Titration: Samples determined positive for antibodies after step II and III were further investigated quasiquantitatively using assays I and III. Samples were diluted in buffer (eg, 1:10 serial dilution steps) until the response in the assay was negative (below the assay cutoff point).
The titer was determined as the last dilution factor with a positive response.
Assay for Neopterin
Serum neopterin levels (normal range: 0.3 to 3.0 ng/mL) were determined with a validated enzyme-linked immunosorbent assay procedure using a test kit (MP Biochemicals, Orangeburg, NY). All specimens were tested immediately after thawing in one assay.
In brief, each of neopterin standards, controls, and patient samples is added to microtiter plates with neopterin-coated wells. Diluted enzyme conjugate is added to all wells except for the nonspecific binding wells. The plates are then incubated at room temperature on a rotator. After that, contents of all wells are aspirated and blotted on absorbent paper. Wells are further washed with diluted wash buffer and aspirated to dryness. Finally, color substrate is added to all wells, incubated for thirty minutes on a rotator and followed by stopping solution. Results are read from absorbance at 450 nm and calculated using the supplied formula from the manufacturer.
Statistical Analysis
Clinical data and the results of the WBC and differential counts were collected on Case Report Forms at the Clinical Study Sites. The neopterin determinations were done under the supervision of T.W. at the University of Pittsburgh. The determinations of binding and neutralizing anti-GM-CSF antibodies were done by T.P. in Turku, Finland. The Case Report Forms and spreadsheets of laboratory test results were all sent to the statistician, S.C., who performed the analysis.
Descriptive statistics were prepared for demographics and baseline disease-related characteristics. Categorical variables were summarized by number and percent; continuous variables by mean and SD, median, and range. WBC, eosinophil, and neopterin values from blood samples obtained at baseline (day 0) and postbaseline (days 15 and 29) were summarized in a descriptive manner. The Wilcoxon signed rank test was used to compare baseline versus postbaseline values. Given the exploratory nature of this study, P-values are not adjusted for multiple testing. 
RESULTS
Characteristics of the Study Population
Of the 53 patients who enrolled in this study, there were 43 who were considered evaluable for determination of the incidence of binding and neutralizing antibodies to GM-CSF. Patients were considered evaluable for antibody formation if they had a serum sample available at baseline and on study day 155, 351, or both. There were 31 male (72.1%) and 12 female (27.9%) patients with a mean age of 56.4 ± 12.04 and a median of 55.0 (range, 31 to 83). Eleven patients were over 65 (25.6%). The baseline melanoma diagnosis and staging characteristics of these patients are shown in Table 1 . The biological effects of the antibodies were reported only for patients who had samples for analysis available at baseline and on study days 155 and 351. There were 32 to 34 patients evaluable for assessment of biological effects of the antibodies, depending on the particular assay involved.
Anti-GM-CSF Antibody Determinations
Of the 43 evaluable patients, none had anti-GM-CSF antibodies at baseline. Forty (93%) of the patients developed anti-GM-CSF binding antibodies by the time of testing on study day 155 and/or 351; 3 patients remained antibody negative. Eighteen (42%) had anti-GM-CSF neutralizing antibodies (or high-titer binding antibodies), and 22 (51%) had binding antibodies only. All patients with neutralizing antibodies also had binding antibodies. No patient had neutralizing antibodies when tested on study day 15 or 29; 1 patient had binding antibodies on study day 15, and 9 patients had binding antibodies on study day 29.
Biological Effects of GM-CSF During the First Cycle of Treatment
During the first cycle of treatment, before the development of neutralizing antibodies to GM-CSF, there was a significant increase in the WBC counts, eosinophil counts as a percentage of the WBC count, and neopterin levels on study day 15, after 2 weeks on GM-CSF therapy (Fig. 2) . The WBC and neopterin levels returned to baseline by study day 29, after 2 weeks rest. The eosinophil counts as a percentage of the WBC count also decreased after 2 weeks rest, but did not reach baseline levels. These analyses only included patients for whom values were available for all 3 study points.
Biological Effects of GM-CSF in Patients With and Without Neutralizing Antibodies in the Sixth and 13th Cycles of Treatment
The presence of neutralizing antibodies abrogated or reduced the biological effects of GM-CSF therapy in patients
Biological assessments during the first cycle of therapy before development of neutralizing antibodies. A, Summary of WBC counts at baseline, study day 15, and study day 29 (n = 49). B, Summary of eosinophil counts as a percentage of the WBC at baseline, study day 15, and study day 29 (n = 46). C, Summary of neopterin levels at baseline, study day 15, and study day 29 (n = 49). The symbol inside the box represents the median. The top and bottom edges of the box represent the 25th and 75th percentiles. The fifth and 95th percentiles are represented by the whiskers extending from the top and bottom of the box. The P-value represents test of within-subject changes from baseline based on the Wilcoxon signed rank test.
after 14 days of administration of GM-CSF in the sixth and 13th cycles of treatment (Fig. 3) . The WBC counts on study days 155 (cycle 6) and 351 (cycle 13) were no different from the baseline counts in patients with neutralizing antibodies, whereas there was a significant increase from baseline levels after 14 days of GM-CSF therapy in patients without neutralizing antibodies (Fig. 3A) . Results were less clear-cut for the impact of neutralizing antibodies on the eosinophil counts as a percentage of the WBC count and also the neopterin levels. In the absence of neutralizing antibodies, these values were significantly increased as compared with baseline after 14 days of GM-CSF therapy. In patients with neutralizing antibodies, the increase was abrogated on study day 351 for the eosinophil count as a percentage of the WBC count (Fig. 3B ) and was abrogated on study day 155 for neopterin levels (Fig. 3C ). For the other study days, the values of these tests were less in the presence of neutralizing antibodies than in their absence, but were still significantly above baseline values.
DISCUSSION
GM-CSF is approved for short-term use for acceleration of myeloid recovery and/or mobilization of hematopoietic progenitor cells in certain circumstances. For that use, consideration of the development of anti-GM-CSF antibodies is not an issue because therapy is short-term and would generally be completed before development of such antibodies would occur. The drug prescribing information states that neutralizing antibodies were detected in 5 of 214 patients (2.3%) after receiving GM-CSF by continuous intravenous infusion (3 patients) or subcutaneous injection (2 patients) for 28 to 84 days in multiple courses. It further states that "1 of 75 patients (1.3%) receiving GM-CSF for Crohn's disease developed neutralizing antibodies." It also states that "The clinical relevance of the presence of these antibodies are (sic) unknown." "Drug-induced neutropenia, neutralization of endogenous GM-CSF activity and diminution of the therapeutic effect of Leukine secondary to formation of neutralizing antibody remain a theoretical possibility." 10 No references are given regarding the incidence of neutralizing or binding anti-GM-CSF antibodies nor are the methods used to detect them described.
In clinical trials, GM-CSF monotherapy is being used as adjuvant therapy of cancer, as a vaccine adjuvant in patients with cancer, and in combination with other agents as therapy of metastatic disease. 7 When GM-CSF is used in cancer therapy, it is administered repeatedly on a long-term basis (months to years). In this circumstance, the development of anti-GM-CSF antibodies is a relevant consideration because in these studies the treatment is given long enough to allow time for the development of antibodies including those which might neutralize the effects of the GM-CSF. Moreover, the administration of intermittent courses is a method known in vaccinations for infectious diseases to induce strong immune responses.
We report herein that 93% of 43 evaluable patients with melanoma treated with GM-CSF had binding antibodies to GM-CSF when determinations were made after 6 or 12 months of therapy, or both. Moreover, 42% of the patients had neutralizing anti-GM-CSF antibodies and these resulted in abrogation or diminution of the biological effects of ongoing GM-CSF administration. We do not know the reason for the apparent discordance of day 155 and day 351 test results in Figure 3B (eosinophil count) and Figure 3C (neopterin). Taken as a whole, however, the data strongly support that the development of neutralizing antibodies abrogates the biological responses to GM-CSF. It seems reasonable that the development of such antibodies that diminish the biological effects of GM-CSF administration might also diminish the therapeutic efficacy of GM-CSF administration. Moreover, we do not know which of the immunologic effects of GM-CSF are relevant to the efficacy and whether this is impacted by the development of neutralizing antibodies. Our study was not designed to evaluate the effect of the development of anti-GM-CSF antibodies on clinical outcome; the number of patients included and the timing of the sampling for antibody analysis was not sufficient to make any statement regarding this.
There have been previous reports of the development of binding and neutralizing antibodies following treatment of patients with GM-CSF, but in most of these studies, the GM-CSF utilized was produced in an Escherichia coli expression system. [28] [29] [30] [31] [32] [33] [34] The E. coli-derived GM-CSF is unlike the yeastderived GM-CSF utilized in the studies reported herein because it is not glycosylated. One report indicated that the antibodies react with unprotected glycosylation sites on the native protein backbone, which are exposed in the nonglycosylated GM-CSF. 28 Therefore, the development of antibodies described in these studies may not correlate with the potential for the development of antibodies following treatment with GM-CSF produced in yeast. The E. coli-derived product is no longer manufactured. Nonetheless, it is noteworthy that in one study, in which the E. coli-derived product was administered to patients with metastatic colorectal carcinoma, results were similar to our findings; a high percentage of patients developed anti-GM-CSF binding antibodies and 40% developed neutralizing antibodies. 33 Moreover, these neutralizing antibodies, but not binding antibodies, were associated with a significant reduction on the GM-CSF-induced expansion of leucocytes, neutrophils, and eosinophils.
There have been several reports of small studies showing the development of anti-GM-CSF antibodies in patients treated with yeast-derived GM-CSF. All 15 patients with prostate cancer treated with yeast-derived GM-CSF developed binding antibodies to GM-CSF and 60% developed antibodies that neutralized the biological activity of GM-CSF in vitro. 35 In 32 patients given GM-CSF by embolization of the hepatic artery, 69% developed binding antibodies and 47% developed neutralizing antibodies to GM-CSF. 36 The authors noted that in patients with neutralizing antibodies, some of the systemic effects of intrahepatic GM-CSF (leukocytosis and transient thrombocytopenia) seem to have diminished. In one report in which GM-CSF was given as a vaccine adjuvant along with cancer-associated peptides in patients with cancer, 13 of the 18 patients (72%) developed antibodies to GM-CSF; none of the analyzed sera expressed neutralizing activity. 37 Our data indicate that 93% of patients with melanoma treated with GM-CSF as adjuvant therapy develop antibodies to GM-CSF. In those with neutralizing antibodies the biological effects of GM-CSF were diminished or abrogated. The development of such antibodies might also diminish the potential clinical benefit of this treatment and should be considered in the design of future clinical trials.
